

> JNC 8 Classification


# HYPERTENSION

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>JNC 8 Classification</b></p></td></tr><tr><td><p><b>Category</b></p></td><td><p><b>Systolic</b></p></td><td><p><b>Diastolic</b></p></td></tr><tr><td><p>Normal</p></td><td><p>&lt;120</p></td><td><p>&lt;80</p></td></tr><tr><td><p>Pre-HTN</p></td><td><p>120–139</p></td><td><p>80–89</p></td></tr><tr><td><p>Stage 1 HTN*</p></td><td><p>140–159</p></td><td><p>90–99</p></td></tr><tr><td><p>Stage 2 HTN</p></td><td><p>≥160</p></td><td><p>≥100</p></td></tr></tbody></table>

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>2017 AHA/ACC BP Classification</b></p></td></tr><tr><td><p><b>Category</b></p></td><td><p><b>Systolic</b></p></td><td><p><b>Diastolic</b></p></td></tr><tr><td><p>Normal</p></td><td><p>&lt;120</p></td><td><p>&lt;80</p></td></tr><tr><td><p>Elevated BP</p></td><td><p>120–129</p></td><td><p>&lt;80</p></td></tr><tr><td><p>Stage 1HTN</p></td><td><p>130–139</p></td><td><p>80–89</p></td></tr><tr><td><p>Stage 2 HTN</p></td><td><p>≥140</p></td><td><p>≥90</p></td></tr></tbody></table>

BP in mmHg. Average ≥2 measurements >1–2 min apart. Confirm stage 1 within 1–4 wk; can Rx stage 2 immediately. (_J Clin HTN_ 2014;16:14; _Circ_ 2018;138:e426)

### 流行病學 (_JAMA_ 2014;311:1424; _Circ_ 2018;138:e426)

• Prevalence ~30% in U.S. adults, ≥44% in African-Americans; M = F

• Of those with HTN, ~3/4 were treated, ~1/2 achieve target BP, ~1/6 were unaware of dx

### 原因 (_JACC_ 2017;71:127)

• **Essential** (95%): onset 25–55 y; ⊕ FHx. Unclear mechanism but ? additive microvasc

renal injury over time with contribution of hyperactive sympathetics (_NEJM_ 2002;346:913).

↑ Age → ↓ art compliance → HTN. Genetics + environment involved (_Nature_ 2011;478:103).

• **Secondary:** Consider if Pt <30 y or if sudden onset, severe, refractory HTN

![](https://i.imgur.com/XaJZfhX.jpg)

### Standard workup

• Goals: (1) identify CV risk factors; (2) consider 2° causes (3) assess for target-organ damage

• History: CAD, HF, TIA/CVA, PAD, DM, renal insufficiency, sleep apnea, preeclampsia; ⊕ FHx for HTN; diet, Na intake, smoking, alcohol, prescription and OTC meds, OCP

• Physical exam: ✔ **BP in both arms;** funduscopic exam, BMI, cardiac (LVH, murmurs), vascular (bruits, radial-femoral delay), abdominal (masses or bruits), neuro exam

• Testing: K, BUN, Cr, Ca, glc, Hct, U/A, lipids, TSH, urinary albumin:creatinine (if ↑ Cr, DM, peripheral edema), ? renin, ECG (for LVH), CXR, TTE (eval for valve 異常, LVH)

• Ambulatory BP monitoring (ABPM): consider for episodic, masked, resistant, or white coat HTN; stronger predictor of mortality than clinic BP (_NEJM_ 2018;378:1509); 24 h target <130/80

### Complications of HTN

• Neurologic: **TIA/CVA**, ruptured aneurysms, vascular dementia

• Retinopathy: stage I = arteriolar narrowing; II = copper-wiring, AV nicking; III = hemorrhages and exudates; IV = papilledema

• Cardiac: **CAD**, **LVH**, **HF, AF**

• Vascular: aortic dissection, aortic aneurysm (HTN = key risk factor for aneurysms)

• Renal: proteinuria, **renal failure**

### 治療 (_J Clin HTN_ 2014;16:14; _Circ_ 2018;138:e426; _NEJM_ 2018;378:636)

• Every ↓ 10 mmHg → 20% ↓ MACE, 28% ↓ HF, 13% ↓ mort. (_Lancet_ 2016;387:957)

• ACC/AHA: initiate BP med if BP ≥130/80 & _either_ 臨床CVD (ischemic heart disease, HF, stroke) _or_ 10-y ASCVD risk ≥10%; otherwise if BP ≥140/90

• JNC8: target <140/90 if <60 y or DM or CKD, <150/90 if ≥60 y without DM or CKD

• In high CV risk without DM, SBP target of <120 (via unattended automated cuff) ↓ MACE & mortality vs. target of <140, but with ↑ HoTN, AKI, syncope, electrolyte 異常 (_NEJM_ 2015;373:2103). Same pattern in subgp ≥75 y (_JAMA_ 2016;315:2673).

• **Lifestyle modifications** (each may ↓ SBP ~5 mmHg)

weight loss: goal BMI 18.5–24.9; aerobic exercise: 90–150 min exercise/wk

diet: rich in fruits & vegetables, low in saturated & total fat (DASH, _NEJM_ 2001;344:3)

limit Na: ideally ≤1.5 g/d or ↓ 1 g/d; enhance K intake (3.5–5 g/d)

limit alcohol: ≤2 drinks/d in men; ≤1 drink/d in women & lighter-wt 病人; avoid NSAIDs

• **Pharmacologic options**

**Pre-HTN:** ARB prevents onset of HTN, no ↓ in 臨床events (_NEJM_ 2006;354:1685)

**HTN:** _choice of therapy controversial, concomitant disease and stage may help guide Rx_

**Uncomplicated:** CCB, ARB/ACEI, or thiazide (chlorthalidone preferred) are 1st line; βB not

_For black, elderly, and ? obese 病人:_ reasonable to start with CCB or thiazide

### \+ CAD (_Circ_ 2015;131:e435): ACEI or ARB (_NEJM_ 2008;358:1547); ACEI+CCB superior to ACEI+thiazide (_NEJM_ 2008;359:2417) or βB+diuretic (_Lancet_ 2005;366:895); may require βB and/or nitrates for anginal relief; if h/o MI, βB ± ACEI/ARB ± aldo antag (see “ACS”)

**\+ HF:** ACEI/ARB/ARNi, βB, diuretics, aldosterone antagonist (see “Heart Failure”)

**\+ prior stroke:** ACEI ± thiazide (_Lancet_ 2001;358:1033)

**\+ diabetes mellitus:** consider ACEI or ARB; can also consider thiazide or CCB

**\+ chronic kidney disease:** ACEI or ARB (_NEJM_ 1993;329:1456 & 2001;345:851 & 861)

• Tailoring therapy: if stage 1, start with monoRx; if stage 2, consider starting with combo (eg, ACEI + CCB; _NEJM_ 2008;359:2417); start at 1/2 max dose; after 1 mo, uptitrate or add drug

• **Pregnancy:** methyldopa, labetalol, & nifed pref. Hydral OK; avoid diuretics; ∅ ACEI/ARB. Targeting DBP 85 vs. 105 safe and ↓ severe HTN (_NEJM_ 2015;372:407).

### Resistant HTN (BP > goal on ≥3 drugs incl diuretic; _HTN_ 2018;72:e53)

• Exclude: 2° causes (see table) and _pseudoresistance:_ inaccurate measure (cuff size), diet noncomp (↑ Na), poor Rx compliance/dosing, white coat HTN (✔ ABPM)

• Ensure effective diuresis (chlorthalidone or indapamide > HCTZ; loop > thiazide if eGFR <30)

• Can add aldosterone antagonist (_Lancet_ 2015;386:2059), β-blocker (particularly vasodilators such as labetalol, carvedilol, or nebivolol), α-blocker, or direct vasodilator

HYPERTENSIVE CRISES

• **Hypertensive emergency:** SBP >180 or DBP >120 with target-organ damage

Neurologic damage: encephalopathy, hemorrhagic or ischemic stroke, papilledema

Cardiac damage: ACS, HF/pulmonary edema, aortic dissection

Renal damage: proteinuria, hematuria, acute renal failure; scleroderma renal crisis

Microangiopathic hemolytic anemia; preeclampsia-eclampsia

• **Hypertensive urgency:** SBP >180 or DBP >120 without target-organ damage

### Precipitants

• Progression of essential HTN ± medical noncompliance (espec clonidine) or ∆ in diet

• Progression of renovascular disease; acute glomerulonephritis; scleroderma; preeclampsia

• Endocrine: pheochromocytoma, Cushing’s

• Sympathomimetics: cocaine, amphetamines, MAO inhibitors + foods rich in tyramine

### 治療 – tailor to 臨床condition (_Circ_ 2018;138:e426)

• AoD, eclampsia/severe preeclampsia, pheo: target SBP <140 (<120 for AoD) in **1 hour**

• Emerg without above: ↓ BP by ~25% in 1 h; to 160/100–110 over next 2–6 h, then 正常 over 1–2 d

• Acute ischemic stroke (w/in 72 hr from sx onset): <185/110 before lysis initiated, otherwise target <220/120 (same SBP goal for ICH)

• Watch UOP, Cr, mental status: may indicate a lower BP is not tolerated

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>IV Drugs for Hypertensive Emergency</b> (<span><i>Circ</i> 2018;138:e426; <i>Stroke</i> 2018;49:46</span>)</p></td></tr><tr><td><p><b>Drug</b></p></td><td><p><b>Dose</b></p></td><td><p><b>Preferred for</b></p></td></tr><tr><td><p>Labetalol</p></td><td><p>20–80 mg IVB q10min or 0.4–2 mg/min</p></td><td><p>AoD, ACS, Stroke, Eclampsia</p></td></tr><tr><td><p>Esmolol</p></td><td><p>0.5–1 mg/kg load → 50–200 µg/kg/min</p></td><td><p>AoD, ACS</p></td></tr><tr><td><p>Nitroprusside<a id="st2"></a><a href="text/part0006_split_010.html#sst2">*</a></p></td><td><p>0.25–10 µg/kg/min</p></td><td><p>Pulm edema</p></td></tr><tr><td><p>Nitroglycerin</p></td><td><p>5–500 µg/min</p></td><td><p>Pulm edema, ACS</p></td></tr><tr><td><p>Nicardipine</p></td><td><p>5–15 mg/h (can ↑ 2.5 mg/h q 5 min)</p></td><td><p>Stroke, AKI, Eclampsia, Pheo</p></td></tr><tr><td><p>Clevidipine</p></td><td><p>1–32 mg/h (can titrate q 5–10 min)</p></td><td><p>Stroke, Pulm edema, AKI, Pheo</p></td></tr><tr><td><p>Fenoldopam</p></td><td><p>0.1–1.6 µg/kg/min</p></td><td><p>AKI</p></td></tr><tr><td><p>Hydralazine</p></td><td><p>10–20 mg q20–30min prn</p></td><td><p>Eclampsia</p></td></tr><tr><td><p>Phentolamine</p></td><td><p>5–15 mg bolus q5–15min</p></td><td><p>Pheo</p></td></tr><tr><td><p>Enalaprilat</p></td><td><p>1.25–5 mg q6h</p></td><td>&nbsp;</td></tr></tbody></table>

[\*](text/part0006_split_010.html#st2)Metabolized to cyanide →Δ MS, lactic acidosis, death. Limit use of very high doses (8–10 μg/kg/min) to <10 min.

• HTN urgency: goal to return to normal BP over hrs to days. Reinstitute/intensify anti-HTN Rx. Additional PO options: labetalol 200–800 mg q8h, captopril 12.5–100 mg q8h, hydralazine 10–75 mg q6h, clonidine 0.2 mg load → 0.1 mg q1h.
